Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-5xszh Total loading time: 0 Render date: 2024-03-29T13:53:21.709Z Has data issue: false hasContentIssue false

139 - Uremia

from PART III - VASCULAR BED/ORGAN STRUCTURE AND FUNCTION IN HEALTH AND DISEASE

Published online by Cambridge University Press:  04 May 2010

Jan T. Kielstein
Affiliation:
Medical School of Hannover, Germany; Stanford University School of Medicine, California
Danilo Fliser
Affiliation:
Medical School of Hannover, Germany;
William C. Aird
Affiliation:
Harvard University, Massachusetts
Get access

Summary

The uremic syndrome can be defined as the deterioration of multiple biochemical and physiological functions in parallel with progressive renal failure. A myriad of compounds, termed uremic toxins, lead to a complex and variable symptomatology – the uremic syndrome. One hallmark of this syndrome is the rapid development of cardiovascular disease. A cornerstone in the complex pathogenesis of this cardiorenal interaction is the endothelium, because it controls many aspects of vascular function. The endothelium produces a wide range of regulatory molecules that, in health, provide a carefully balanced antiatherogenic environment. In contrast, endothelial dysfunction has been demonstrated repeatedly in renal failure, is present in the absence of anatomically obvious disease, and appears to be useful in the prediction of morbidity and mortality in other cardiovascular risk groups. One of the most important and intensively studied mediators of endothelial function is nitric oxide (NO). Numerous preclinical and clinical studies have shown that NO bioavailability is reduced in chronic kidney disease (CKD). NO deficiency contributes to the progressive nature of CKD, endothelial dysfunction, and associated risk for cardiovascular events. Mechanisms of NO deficiency are likely multifactorial. They include substrate limitation, competitive inhibition of NO synthase (NOS) by endogenous NOS inhibitors, and premature quenching of NO by free radicals. Recent evidence points to an important role for the NOS inhibitor, asymmetric dimethylarginine (ADMA). This compound has a wide range of actions that are consistent not only with its role in uremia pathophysiology but also as a common pathway through which cardiovascular risk factors exert their deleterious effects. Unlike other uremic toxins, it also predicts for progression of renal disease.

Type
Chapter
Information
Endothelial Biomedicine , pp. 1278 - 1286
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Uremia
    • By Jan T. Kielstein, Medical School of Hannover, Germany; Stanford University School of Medicine, California, Danilo Fliser, Medical School of Hannover, Germany;
  • Edited by William C. Aird, Harvard University, Massachusetts
  • Book: Endothelial Biomedicine
  • Online publication: 04 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511546198.140
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Uremia
    • By Jan T. Kielstein, Medical School of Hannover, Germany; Stanford University School of Medicine, California, Danilo Fliser, Medical School of Hannover, Germany;
  • Edited by William C. Aird, Harvard University, Massachusetts
  • Book: Endothelial Biomedicine
  • Online publication: 04 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511546198.140
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Uremia
    • By Jan T. Kielstein, Medical School of Hannover, Germany; Stanford University School of Medicine, California, Danilo Fliser, Medical School of Hannover, Germany;
  • Edited by William C. Aird, Harvard University, Massachusetts
  • Book: Endothelial Biomedicine
  • Online publication: 04 May 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511546198.140
Available formats
×